Nektar Therapeutics reports one-year Rezpegaldesleukin durability
The company says its Rezpegaldesleukin has shown durable and deepening response over one year of treatment.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.